DISC1 and psychiatric disorder: Treatment with pharmacological inhibitors of GSK3β can completely ameliorate the DISC1 loss-of-function-induced progenitor proliferation defects and behavioral abnormalities, which illustrates the exciting opportunity to develop small-molecule modulators of the Wnt pathway as prototypical drug treatments for psychiatric diseases.